Merck Publishes 2013 Global Corporate Responsibility Report


August 5, 2014 12:00 pm ET

Merck (NYSE:MRK), known as MSD outside of the United States and Canada,
today issued its 2013 global corporate responsibility report. The
report, available at,
focuses on the company’s corporate responsibility activities, progress
and performance during 2013 in four priority areas where Merck is
positioned to have a positive impact: Access to Health, Environmental
Sustainability, Employees and Ethics and Transparency.

Highlights from the 2013 report include:

  • Reached more than 340 million people through our major programs and
    partnerships to help address barriers to access
  • Continued to work with partners to help ensure that infants and girls
    in the poorest countries have access to our vaccines
  • Through our ground-breaking partnership to treat river blindness,
    Colombia became the first country to eliminate the disease
  • Working in close collaboration with more than 75 implementing
    partners, Merck for Mothers initiated more than 50 projects in
    30 countries
  • Implemented a new streamlined environmental strategy that focuses on
    the issues that are most important to our business and our stakeholders
  • Narrowed our environmental sustainability goals to the critical few
    that align with our business and focus on key global environmental
  • Leveraged the scientific and business skills of our employees through
    the Richard T. Clark Fellowship for World Health to help address the
    health needs of underserved populations
  • Recognized for the 11th consecutive year as a Top 50
    Company for Diversity by DiversityInc
  • Ranked No.1 in the CPA-Zicklin Index of Corporate Political Disclosure
    and Accountability for three consecutive years

Merck continues to use several external guidelines and measurement
frameworks to inform the scope of its reporting, including the Global
Reporting Initiative (GRI G4) Guidelines, the Millennium Development
Goals, the Access to Medicine Index and the United Nations Global

In addition to the comprehensive report at,
Merck has published an executive summary highlighting various programs
and partnerships that exemplify the company’s corporate responsibility
commitments. The executive summary is available at

Future information will be provided through a Twitter
conversation at #BeWell.

About Merck

Today’s Merck is a global healthcare leader working to help the world be
well. Merck is known as MSD outside the United States and Canada.
Through our prescription medicines, vaccines, biologic therapies, and
consumer care and animal health products, we work with customers and
operate in more than 140 countries to deliver innovative health
solutions. We also demonstrate our commitment to increasing access to
healthcare through far-reaching policies, programs and partnerships. For
more information, visit
and connect with us on Twitter,
and YouTube.

Merck Forward-Looking Statement

This news release includes “forward-looking statements” within the
meaning of the safe harbor provisions of the United States Private
Securities Litigation Reform Act of 1995. These statements are based
upon the current beliefs and expectations of Merck’s management and are
subject to significant risks and uncertainties. If underlying
assumptions prove inaccurate or risks or uncertainties materialize,
actual results may differ materially from those set forth in the
forward-looking statements.

Risks and uncertainties include but are not limited to, general industry
conditions and competition; general economic factors, including interest
rate and currency exchange rate fluctuations; the impact of
pharmaceutical industry regulation and health care legislation in the
United States and internationally; global trends toward health care cost
containment; technological advances, new products and patents attained
by competitors; challenges inherent in new product development,
including obtaining regulatory approval; Merck’s ability to accurately
predict future market conditions; manufacturing difficulties or delays;
financial instability of international economies and sovereign risk;
dependence on the effectiveness of Merck’s patents and other protections
for innovative products; and the exposure to litigation, including
patent litigation, and/or regulatory actions.

Merck undertakes no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events or
otherwise. Additional factors that could cause results to differ
materially from those described in the forward-looking statements can be
found in Merck’s 2013 Annual Report on Form 10-K and the company’s other
filings with the Securities and Exchange Commission (SEC) available at
the SEC’s Internet site (

For Merck
Lainie Keller, 908-423-4187
Justin Holko, 908-423-5088

Unsubscribe from email alerts